ArticleJACC. Case reports2026
Residual Graft Pathology During CABG as a Minimally Invasive Diagnostic Pathway for Transthyretin Amyloidosis.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcomitant coronary artery disease is not uncommon in cardiac amyloidosis (CA), yet diagnostic pathways remain challenging when myocardial ischemia and CA coexist. CASE SUMMARY: We describe a 72-year-old man presenting with heart failure and severe 3-vessel disease in whom transthyretin amyloidosis was ultimately diagnosed using residual arterial graft tissue obtained during urgent coronary artery bypass grafting (CABG). Histologic examination of the residual left and right internal thoracic arteries and radial artery revealed transthyretin amyloidosis amyloid deposition, enabling rapid, minimally invasive confirmation of systemic amyloidosis at a time when bone scintigraphy risked false-positive interpretation due to myocardial ischemia and endomyocardial biopsy posed a procedural risk. The patient demonstrated marked clinical improvement after CABG and was started on vutrisiran. DISCUSSION: This case highlights arterial graft pathology as a practical and rarely used diagnostic opportunity for suspected CA in patients undergoing CABG, suggesting a potential role for graft-based screening in selected individuals. TAKE-HOME MESSAGES: Residual arterial graft tissue obtained during CABG may provide a practical, minimally invasive means of confirming systemic amyloidosis when nonbiopsy pathways may be inconclusive or endomyocardial biopsy poses procedural risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.